4Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. NCCLS documents M100-S15 [ S]. CLSI/NCCLS ,2005 :25.
5Venditti M, Monaco M, Micozzi A, et al. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies [ J ]. Clin Microbiol Infect, 2001,7 (1) :37 -39.
6Tatman-Otkun M, Gurcan S, Ozer B, et al. The antimicrobial susceptibility of Stenotrephomonas maltophilia isolates using three different methods and their genetic relatedness[ J]. BMC Microbiology,2005, 5(1) :24 -29.
7Avison MB, Higgins CS, von-Heldreieh CJ, et al. Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia [ J ]. Antimicrob Agents Chemother, 2001,45(2) :413 -419.
8Lambert T,Pioy MC, Denis F, et al. Characterization of the chromosomal aac(6, ) -1z gene of Stenotrophonomas mahophilia[ J]. J Antimicrob Chemother,2000,46(6) :2 366 -2 374.
